COA Applauds the Senate Finance Committee for PBM Hearing as Part of National Efforts to Shed Light on PBM Abuses and Lower Drug Prices More Investigation and Oversight Needed to Examine Adverse Impact of PBM Abuses on Patient Care Statement from Ted Okon, Executive Director, Community Oncology Alliance (COA): Today’s Senate Finance Committee hearing
About nferreyrosThis author has not yet filled in any details.
So far nferreyros has created 11 blog entries.
COA Hosts Cancer Care Teams, Advocates, and Stakeholders for Largest Community Oncology Conference Ever
Pharmacy Benefit Manager (PBM) Abuses and Patient Horror Stories Take Center Stage at Annual COA Conference Physicians, Administrators, Nurses, Pharmacists, Advocates, and Stakeholders Come Together to Share Latest Innovations in Cancer Care The most successful Community Oncology Alliance (COA) Community Oncology Conference ever, wrapped up today featuring a record-breaking nearly 1,600 community oncology physicians,
COA Submits Formal Comments to CMS on Proposed CAR-T Cell Therapy Coverage Determination Today the Community Oncology Alliance (COA) submitted a formal comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding a proposed national coverage determination memo for CAR-T cell therapy. While COA is pleased that CMS is moving in the
Introduction In 2018, the assault on patient access to local and affordable cancer care provided by community oncologists, upon which over half of all Americans rely, continued. The work of the Community Oncology Alliance (COA) repelled, repealed, or slowed down a record number of significant challenges to patients and practices, including proposed cuts to
COA Commends Trump Administration for Plan to Lower Drug Costs for Patients The Community Oncology Alliance (COA) applauds President Donald Trump, Health and Human Services Secretary Alex Azar, Inspector General Daniel Levinson, and HHS staff for the just released, ambitious proposal to overhaul the nation’s secretive drug rebate system. This move will lower drug prices
The Myth of Perverse Physician Incentives: Examining Research and Accusations in the Medicare Part B ASP Reimbursement System for Oncology
A frequent accusation aimed at physicians who prescribe and administer medications within the Medicare Part B system is that they are motivated by a perverse incentive of higher reimbursement to prescribe expensive drugs. For oncologists, who utilize potentially life-saving, but increasingly very expensive drugs in treating some of the nation’s sickest patients, this is a
The Honorable Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-5528-ANPRM P.O. Box 8016 Baltimore, MD 21244-8013 Re: Medicare Program; International Pricing Index Model for Medicare Part B Drugs; CMS-5528- ANPRM Dear Administrator Verma: On behalf of the Board of Directors of the Community Oncology Alliance (COA),
Peter Mucchetti, Esq. Peter.J.Mucchetti@usdoj.gov Antitrust.email@example.com Chief, Healthcare and Consumer Products Section, Antitrust Division, Department of Justice 450 Fifth Street NW, Suite 4100 Washington, DC 20530 RE: United States of America v. CVS Health Corporation and Aetna Inc. Dkt. No.: 1:18-cv-02340 Dear Mr. Mucchetti: The Community Oncology Alliance (“COA”) submits this letter on behalf of
New CPAN Chapter Gives Cancer Patients, Survivors A Forum to Speak Out for Access to Local Cancer Care The Cancer Center of Middle Georgia (CCMG) at the practice’s offices at 2400 Bellevue Road, Suite #26, in Dublin, launched a new local chapter of the Community Oncology Alliance Patient Advocacy Network (CPAN), which will advocate for
We are about to enter a critical period for community oncology. Far-reaching Medicare policies are under consideration in Washington that have the potential to completely transform your practice and, quite possibly, ability to survive. From the way you and your practice are reimbursed; to how you acquire and deliver complex cancer drugs; to your ability